Author's response to reviews

Title: From Palliative to Curative Treatment - A case of stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with bevacizumab and surgery

Authors:

Karolina Vernmark (karolina.vernmark@regionostergotland.se)
Maria Albertsson (maria.albertsson@regionostergotland.se)
Bergthor Björnsson (bergthor.bjornsson@regionostergotland.se)
Thomas Gasslander (thomas.gasslander@regionostergotland.se)
Per Sandström (per.sandstrom@regionostergotland.se)
Xiao-Feng Sun (xiao-feng.sun@liu.se)
Annika Holmqvist (annika.holmqvist@regionostergotland.se)

Version: 4 Date: 20 October 2015

Author's response to reviews: see over
Dear Editor,

Thank you for your email, along with one of the two reviewers’ additional comments, on our manuscript version 3. We have carefully revised the manuscript following the reviewer no 2’s additional comments, and resubmit a revised manuscript with changes highlighted. The detailed responses to the comments are as follows:

Reviewer no 2, Dr Andrew Ko – Comments on manuscript version 3.

"The authors state that, "To our knowledge no clinical study so far has specifically analyzed the effect of LDM chemotherapy when combined with bevacizumab."
They may wish to reference Kelley et al, Br J Cancer 2013 (A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer)."

Response: The suggested article has been cited, along with a recently published review of studies investigating the effect of the combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy. The two articles have been added to the list of References (no 19 and 20). We have added lines 171-182 on pages 7-8 to clarify that there are several studies conducted that have demonstrated the efficacy of LDM chemotherapy and bevacizumab, although the results can be difficult to interpret do to generally low patient counts and lack of control arm. A short summary of the one study we know of that included patients with metastatic colon cancer have been added. Changes are highlighted in yellow in the revised manuscript.

"Quality of written English: Needs some language corrections before being Published"

Response: Changes have been made according to suggestions from our American colleague Dr Russell Pepin. Changes in the language are highlighted in green in the revised manuscript. Line 294, page 14 has been added to Acknowledgements.
Yours Sincerely,

Karolina Vernmark